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Abstract. Numerous strategies have been proposed to overcome the 
blood-brain barrier (BBB) and efficiently deliver therapeutic agents to 
the brain. One of these strategies consists of linking the 
pharmacologically active substance to a molecular vector that acts as a 
molecular Trojan Horse and is capable of crossing the BBB using a 
receptor-mediated transcellular transport system of the brain capillary 
endothelial cells (BCECs). The transferrin receptor (TfR) is related to 
a transcytosis process in these cells, and the 8D3 monoclonal antibody 
(mAb), directed against the mouse TfR, is able to induce a receptor 
response. Thus, the 8D3 antibody could be a potential molecular 
Trojan Horse to transport pharmacologically active substances across 
the BBB. On these bases, a series of experiments were performed 
where the 8D3 antibody was conjugated to different cargoes,                    
the resulting constructs were administered in vivo to mice, and the 
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distribution and intracellular mechanisms that these constructs undergo at the BBB were 
studied. Our results indicated a TfR-mediated and clathrin-dependent internalization 
process by which the 8D3-cargo constructs enters the BCEC. The resulting endocytic 
vesicles follow at least two different routes. On one hand, most vesicles enter intracellular 
processes of vesicular fusion and rearrangement in which the cargo is guided to late 
endosomes, multivesicular bodies or lysosomes. On the other hand, a small but not 
negligible percentage of the vesicles follow a different route in which they fuse with the 
abluminal membrane and open towards the basal lamina, indicating a potential route for 
the delivery of therapeutic substances. In this route, however, the 8D3−cargo remain fixed 
to the abluminal membrane, indicating that the 8D3 is maintained linked to the TfR, and 
the cargo does not go beyond the basal membrane. Altogether, different optimization 
approaches need to be developed for efficient drug delivery, but receptor-mediated 




       
      The blood-brain barrier (BBB) is a well-coordinated and highly selective 
barrier whose main function is to regulate brain homeostasis and the 
transport of endogenous and exogenous substances between the blood and 
the brain. It permits the selective brain uptake of nutrients and impedes the 
entrance of potentially harmful substances and pathogenic organisms into the 
brain [1-3]. Due to this restrictive nature of the BBB, the transport of 
therapeutics from the blood to the brain results extremely difficult, and has 
become a major pharmaceutical challenge in recent decades [1]. Only 
lipophilic molecules with a molecular mass under a 400-600 Da threshold 
are capable of crossing the BBB [1, 4]. Moreover, efflux transport systems 
such as P-glycoprotein, which are present in the brain capillary endothelial 
cells (BCECs), are able to export some of these small drugs back to the 
blood [5]. Hence, 98% of all small drugs and almost 100% of large molecule 
drugs are unable to cross the barrier [6]. 
 Different strategies have been proposed to transport neurotherapeutics 
from the blood into the brain, including the utilization of the receptor-
mediated transport (RMT) mechanisms present in the BCECs [1, 7]. The 
transferrin receptor (TfR), which is abundant in brain capillaries [7], has 
been extensively studied. Some monoclonal antibodies (mAbs) directed 
against this receptor have shown to be useful tools for studying                      
TfR-mediated transcytosis across the BBB in rodents, and have been 
proposed as possible vectors or molecular Trojan Horses to transport 
substances across the BBB [8-14]. Some studies have concluded that               
anti-TfR mAbs accumulate in BCECS and do not cross the BBB, while other 
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studies, most of which have used the capillary depletion method or indirect 
outcome measures such as protein expression or enzymatic activity, have 
concluded that mAbs and/or their cargo are successfully transported across 
the BBB [8, 12, 14-16]. Thus, whether or not mAbs directed against the TfR 




Figure 1. The proposed model for the transport of drugs across the BBB using RMT 
and anti-TfR mAbs includes: 1) the endocytosis of the drug-mAb/TfR on the luminal 
membrane and 2) the exocytosis of the mAb-drug on the basolateral membrane and 
receptor recycling. However, other possible destinations for the drug-mAb/TfR 
complex can be possible, as: 3) accumulation of the drug-mAb/receptor complex 
inside the BCEC, and 4) mAb and drug degradation. 
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 The rat mAb 8D3, directed against the mouse TfR, has been proposed as 
a potential carrier candidate to transport substances across the mouse BBB. 
This mAb was first produced by Britta Engelhardt’s research group in the 
Max Planck Institute (Bad Nauheim, Germany) [11], and some active 
substances that have been used as a cargo, seemed to achieve better results in 
crossing the BBB when attached to the 8D3 [14, 17-21]. However, the 
intracellular mechanisms the mAb or the mAb-cargo construct undergo 
inside BCECs still need to be elucidated. 
 The lack of more exhaustive analysis by means of microscopic 
techniques that allow the detection and direct localization of the mAb and / 
or cargo at a cellular and subcellular level, as well as the existing 
unknowledge regarding the cellular and intracellular processes that take part 
in the processing of these molecular Trojan Horses at the BBB level, have 
been the basis for the approach of this work. 
 In order to test the viability of the 8D3 as a potential carrier, a series of 
experiments were performed where the 8D3 antibody was conjugated to 
different cargoes, the resulting constructs were administered in vivo to mice, 
and the distribution and intracellular mechanisms that these constructs 
undergo at the BBB were studied. 
  
1. The 8D3 antibody is able to recognize TfR and trigger the 
internalization of the cargo which is conjugated to [adapted from 
22] 
 
 First of all, in order to test the reactivity of the 8D3 antibody for the TfR 
present in the luminal membrane of the BCECs, an inmmunohistochemical 
procedure was applied using 8D3 as the primary antibody on cryostat 
sections of mouse brain (male ICR-CD1). As expected, the staining 
permitted the visualization of brain capillaries (Figure 2A), where the BBB 
is present and the TfR is localized in the endothelial cells, but did not allow 
to visualize the vessels of the choroid plexus, in which the capillaries are 
fenestrated and the endothelial cells do not present TfR. 
 The second step was to test whether this antibody could be detected in 
brain capillaries after in vivo administration. For this purpose, a second 
group of animals underwent i.v. administration of 8D3 antibody in the 
caudal vein, and after 20 min of recirculation, brain samples were taken and 
localization of the 8D3 was determined via immunohistochemical 
techniques. The results showed that, in the same regions observed by direct 
immunohistochemistry, the brain capillaries contained the 8D3 antibody 
(Figure 2B1 and 2C1). They were stained with only the secondary antibody 
directed against 8D3, indicating that intravenously administered 8D3 
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antibody reaches and attaches to the BCECs. A simultaneous staining 
performed with laminin (a component of the basal membrane used to delimit 
the abluminal wall of the capillaries) showed that the laminin staining 
surrounded the 8D3 staining, suggesting that the antibody does not complete 
transcytosis, is unable to reach the cerebral parenchyma and remains inside 
the endothelial cell (Figure 2C3). It can also be observed that the 8D3 
antibody presented a granular pattern (Figure 2C1 inset), which contrasted 
with the fine and smooth staining of the laminin (Figure 2C2 inset). This 
granular pattern suggested some endocytic process by which the antibody 
could have been internalized inside the BCEC. 
 After observing that the intravenously administered 8D3 antibody can be 
localized in the wall of the brain capillaries, our next goal was to develop an 
immunocomplex (IC) composed of the 8D3 antibody (molecular                            
Trojan Horse) and Fab’ fragments (that simulated a cargo) attached to the 
8D3, and study the capacity of this antibody to transport the Fab’ fragment 
across the BBB. A third group of animals received an i.v. injection of the 
8D3-Fab’ ICs in the optimal proportions established previously                                             
(1:4 weight/weight 8D3/Fab’). After different times of recirculation                   




Figure 2. (A) Immunohistochemical labeling of mouse brain sections with the 
primary rat 8D3 MAb targeting murine TfR and the secondary AF488 anti-rat IgG 
(green color). (B and C) Brain sections from a representative mouse which received 
the 8D3 antibody intravenously. The sections were stained with an anti-laminin 
antibody as a primary, and both the AF555 (red color) and the AF488 anti-rat IgG 
(green color) as secondary antibodies to detect, respectively, the anti-laminin 
antibody and the administered 8D3. It can be observed that, after intravenous 
administration of 8D3, the antibody could be found in brain capillaries but not in 
parenchyma. The granular pattern of the 8D3 staining (C1 inset) contrasts with the 
uniform staining of the laminin (C2 inset). Scale bars: 10 µm.  [adapted from 22]. 
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brains were obtained in order to study the localization and colocalization of 
both components of the IC by immunohistochemistry. Using a fluorescence 
microscope, we observed that both components localized in the wall of the 
capillaries (Figure 3A1 and 3A2), with a clear granular pattern and high 
colocalization between the two stains (Figure 3A3), indicating that both 
components of the IC remain attached or at least where in the same 
endosomal compartment. The simultaneous staining with laminin (Figure 3B 
and C) demonstrated that both 8D3 and Fab’ cargo get externally delimited 
by this marker. In control animals that received an i.v. injection of an IC 




Figure 3. Localization of the components of the IC (8D3:Fab’ 1:4) in brain 
capillaries of the hippocampus. (A) Localization of the 8D3 antibody with a 
secondary AF488 (green color) and of Fab’ components with a secondary AF555 
(red color). High colocalization (yellow color) of 8D3 and Fab’ can be observed, and 
both components exhibit a granular pattern. (B and C) Simultaneous staining of 
laminin and 8D3 or Fab’ components. 8D3 and Fab’ seem to be localized inside the 
region delimited by the basal lamina. Scale bars: 10 µm. [adapted from 22]. 
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the IgG nor the Fab’ staining was observed in brain sections, hence 
indicating that the IC is not retained in the BCECs if it does not include an 
antibody directed against the TfR. 
 In order to study the maintenance and stability of the IC in the wall of 
the blood vessels through the different recirculation times tested (2.5 h vs              
24 h), we used the Fluorescence Resonance Energy Transfer (FRET) 
technique. As the ICs are formed by 8D3 rat IgG and goat anti-rat IgG Fab’ 
fragments, they can be simultaneously immunostained with AF488 donkey 
anti-rat IgG and AF555 donkey anti-goat IgG. Microscope images of AF488 
emission (green color) directly stimulated by its excitation frequency (blue 
color), were taken before and after bleaching AF555. When AF555 is 
bleached, it is incapable of capturing the emission of the AF488 that is 
emitted near to it (energy transfer), and thus, the detection of the donor 




Figure 4. Process performed for one blood capillary using the FRET technique. 
When AF555 is bleached, it is incapable of capturing the green emission of the 
AF488 that is emitted near to it (energy transfer), and thus the observed donor 
emission (D2) after bleaching the AF555 is bigger than before bleaching (D1).                  
A: acceptor emission, D: donor emission, 1: before bleaching, 2: after bleaching 
[adapted from 22].  
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 Thus, by quantifying the increase of the detected donor emission, an 
indication of the number of molecules implicated in the energy transfer, i.e. 
molecules of AF488 and AF555 that are near one to the other, can be 
obtained. Statistical analysis indicated that the time of recirculation had a 
significant effect on the increase of the detected donor emission, being the 
increase higher in animals that were sacrificed 2.5 h after IC administration 
than in animals sacrificed 24 h later. As AF488 and AF555 stain respectively 
the 8D3 and the Fab’ fragments, the increases also indicate the amount of 
8D3 and Fab’ fragments that persist attached on the original ICs. Thus, the 
colocalization of the fluorescent signals inside the endothelial cells 
decreased with time, indicating that ICs are processed and Fab’ fragments 
probably separated from 8D3. 
 On the other hand, in order to directly visualize the 8D3 antibody and 
avoid the immunohistochemical processing, a fourth group of animals 
received an i.v. injection of 8D3 previously marked with fluorescein 
isothiocyanate (8D3
FITC
). Likewise, another group of animals underwent i.v. 









 (data not shown) showed similar 
staining patterns in comparison with the anterior cases, being once again 
externally delimited by the laminin. However, a higher signal amplification 
was observed in the case of the 8D3-Fab’
FITC
 with respect to 8D3
FITC
, 




Figure 5. Localization of intravenously administered 8D3-Fab’FITC (green color) and 
immunohistochemical staining with a primary antibody against laminin and 
secondary AF555 anti-rabbit IgG (red color) in brain capillaries of the hippocampus. 
The fluorescence of the administered IC is confined to the region delimited by 
laminin. Scale bar: 10 µm [adapted from 22]. 
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 As concluding remarks, we observed that the 8D3 antibody, with or 
without a cargo attached, is able to bind the TfR present in the luminal 
membrane of the BCECs and gets retained in these cells, probably in 
intracellular vesicles. Inside these cells, some kind of IC processing is 
produced, and after 24 h of recirculation, there were less Fab’ fragments near 
the 8D3 molecules than after 2.5 h of recirculation. In any case, the 
components of the IC were never observed beyond the basal membrane or 
reaching the brain parenchyma. Thus, nor the 8D3 neither the IC seem to 
have completed transcytosis. These results cast doubt on the transcytotic 
capacity of the 8D3 antibody, and contradict previous studies that advocate 
an efficient transcytosis. However, the highest magnification level the 
optical microscopy allows us to work with, is perhaps not enough to draw a 
reliable conclusion, and we cannot rule out that an undetectable amount of 
antibody could have crossed the BBB.  
 
2. 8D3-cargo constructs at the BBB: Intracellular mechanisms 
and subcellular localization [adapted from 23] 
 
 In view of the results obtained, the next step to move along in the study 
of the 8D3 antibody was to monitor in a more precise way the antibody 
localization and clarify which intracellular processes take part at the BBB. 
 For this purpose, gold nanoparticles (AuNPs) were coated with the 8D3 
antibody, and using transmission electron microscope (TEM) techniques, the 
passage of these AuNPs across the BBB and their dynamics inside BCECs 
after in vivo administration were studied in mice. AuNPs not only can be 
directly observed by TEM, but also can be considered as the cargo to be 
transported by the 8D3. To form the 8D3-AuNP conjugates, the 8D3 
antibody was covalently attached to AuNPs measuring 20 nm in diameter. 
The 8D3:AuNP ratio for the conjugates was approximately of 30:1. The 
conjugate was intravenously administered to ICR-CD1 mice that were 
distributed into four different groups, each of them with a different time of 
recirculation (10 min, 30 min, 2.5 h and 24 h). Once the corresponding time 
had passed, animals were anesthetized and intracardially perfused with 
paraformaldehyde and glutaraldehyde, and brains were then removed and 
processed for TEM. 
 Image analysis permitted the study of the AuNP localization at a 
subcellular level and at the different times of recirculation. The localization 
patterns varied over time. At the shortest time of recirculation (10 min), the 
AuNPs were mostly attached to the lumen of the capillary, in clathrin-coated 
pits or internalized in endocytic vesicles of the endothelial cells that 
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contained one or few AuNPs inside. The 8D3-AuNP conjugates are 
individually internalized, as no clathrin-coated pits containing more than one 
AuNPs were observed. No AuNPs were observed in the brains of the control 
mice, which had been administered with intravenous non-specific IgG-AuNP 
conjugate, confirming that the internalization depended on the presence of 
the 8D3. At 30 min of recirculation, the percentage of AuNPs yet to be 
internalized had decreased, and some of the intracellular vesicles contained a 
higher number of AuNPs. At the highest times of recirculation (2.5 h and              
24 h), almost a 100% of the AuNPs observed had already been internalized 
in the BCECs, and many of the AuNP-containing vesicles had a higher 
number of particles inside them (up to 23 AuNPs in two cases). Some of the 
AuNPs were found in the basal lamina of the endothelium, bordering the 
abluminal membrane of the BCECs, which would suggest that 8D3-AuNP 
complex had completed transcytosis but remained attached to the TfR. Most 
of these AuNPs were observed at 2.5 h of recirculation, being 4.6% the 
percent respect to the total number of the AuNPs observed at this time 




Figure 6. Percentage of AuNPs on the luminal surface [i.e. particles attached to the 
luminal membrane (LMP) and particles in clathrin-coated pits (CPP)] and basal 
membrane (BMP) for each recirculation time. Mean values and standard errors are 
shown. L: Lumen; BM: basal membrane. At 2.5 h of recirculation, all particles have 
been internalized, and the maximum percentage of particles that reach the basal 
membrane is obtained [adapted from 23]. 
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 Thus, at the shortest times of recirculation (10 min and 30 min), the 
predominant localization patterns were the lumen of the capillary, the 
clathrin-coated pits and the endocytic vesicles containing small amounts of 
AuNPs. Apart from the AuNPs that reach the basal lamina, the number of 
AuNPs per vesicle increased over time, so that at the longer times of 
recirculation, the vesicles containing high amounts of AuNPs was the main 
localization pattern (Figure 7). 
 The quantitative analysis performed with the data obtained permitted to 
establish and characterize a time-dependent trafficking pattern of endocytic 
internalization and endosomal processing of the conjugate at the BBB 
(Figure 8). The 8D3-AuNP conjugates are individually internalized within 
BCECs through a clathrin-dependent endocytosis process. The resulting 
AuNP-containing vesicles then follow at least two different routes. On one 
hand, most vesicles undergo intracellular processes of vesicular fusion and 
rearrangement in which the AuNPs end up accumulating in late endosomes, 




Figure 7. 3D contour graph obtained by adjusting, with distance weighted                   
least-squares, the percentage of particles to the localization and the recirculation time. 
LMP: particles sited on luminal membrane; CPP: coated pit particles; Vi: vesicle 
containing i AuNPs. Particles sited on basal membrane are not plotted. L: Lumen; 
BM: basal membrane [adapted from 23]. 
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Figure 8. Deduced trafficking of the 8D3−AuNPs across the mouse BBB [adapted 
from 23]. 
 
On the other hand, a small percentage of vesicles (containing just one AuNP) 
follow a different route in which they fuse with the abluminal membrane and 
open to the basal lamina, which suggests an endosomal escape and 
transcytosis completion. However, the conjugates get retained in the basal 
lamina and do not reach the brain parenchyma. 
 Given the controversy regarding the possible use of anti-TfR antibodies 
to transport substances across the BBB, this study provided new information 
that may clarify some questions that are yet to be answered concerning the 
dynamics and intracellular processes the cargo undergo when coated with 
the 8D3 antibody. The results suggest that the 8D3 antibody may be a useful 
Trojan Horse to transport substances toward the BCECs. The 8D3 is able to 
drive the cargo to the brain capillaries and internalize it into the BCECs. 
This makes that a considerable amount of the intravenously administered 
cargo gets retained in the cerebral area instead of targeting another tissues or 
organs, and moreover, it makes the cargo to overcome the first barrier (the 
luminal membrane) reaching the inside of the endothelial cells. Although the 
cargo is mainly retained inside the BCEC, a small but not negligible 
percentage of particles escape from the conventional endosomal route, 
complete transcytosis and access the basal lamina, probably as a result of a 
different and uncommon endosomal sorting. This small percentage do not 
reach the brain parenchyma, perhaps due to the strong bond between the 8D3 
and the TfR. Nevertheless, it should not be considered impossible for the 
cargo to reach the brain parenchyma once it has reached the basal lamina if 
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the linkage between the Trojan Horse and the transported cargo had 
properties that permitted the cargo to dissociate from the carrier. 
 
3. Serial block-face scanning electron microscopy: A tool to       
three-dimensionally study the trafficking of mAb-cargo 
conjugates at the BBB [adapted from 25] 
 
 The results obtained by TEM provided relevant information at an 
ultrastructural level concerning the dynamics of the AuNPs when transported 
by the 8D3 antibody after in vivo administration. However, the                 
two-dimensional (2D) image analysis entailed a series of limitations that we 
decided to overcome by carrying out a three-dimensional (3D) structural 
study that could give more insight into the transport of molecules across the 
BBB, and more knowledge on the trafficking of the AuNPs. 
 Serial block-face (SBF) imaging is a recently developed imaging 
technique that uses scanning electron microscopy (SEM) to acquire serial 
images and reconstruct large tissue regions in 3D [24]. In SBF-SEM, surface 
areas of the embedded tissue blocks are serially cut and removed with the 
built-in diamond knife in the SEM chamber between the cycles of SEM 
imaging. Because the consecutive areas of tissue are imaged with surface 
milling, this method generates largely pre-aligned images, which speeds up 
3D reconstruction of the target structures. The objective of this work was 
first to determine whether the SBF-SEM resulted appropriate to reconstruct 
BBB segments and AuNP-containing endocytic vesicles, and if so, try to 
obtain additional information that would complement our previous 2D 
studies. This technique has been extensively used to explore the connectivity 
of the neural network, but only rarely to study the structure of the BBB, and 
no SBF-SEM data exist on the transport of molecules across this barrier. 
 To this end, we performed the same experimental design as for the 2D 
TEM study, but it was only reproduced at 2.5 h of recirculation (the time of 
recirculation where more diverse localization patterns were observed). After 
the mice brains were processed for SBF-SEM, the stained blocks were 
imaged using a Gatan 3View serial block-face imaging system installed on a 
FEI Quanta 250 FEG scanning electron microscope. The resulting datasets 
were assembled into volume files and aligned. 3D reconstruction of the 
desired structures was performed in image stacks using Imaris 8.0.2 and 
Imaris 7.2 software.  
 In a first attempt to perform a 3D reconstruction of the BBB and to 
observe the localization of the AuNPs, capillary segments (up to 10 µm long 
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along the z axis) from different brain samples were fully 3D rendered 
using low-magnification image stacks (10,000-25,000×). These image 
stacks were obtained using an incident electron beam with an energy of 
2.3-2.4 kV and spot size 3, and a chamber pressure of 50 Pa was applied to 
scan across the samples at a pixel dwell time of 60 µs. This level of 
magnification allowed us to identify the cellular components that form the 
neurovascular unit, such as BCECs, the basal lamina, pericytes, astrocytes, 
and three-dimensionally reconstruct them by manually tracing the area in 
each plane and surface rendering next (Figure 9). However, the AuNPs 
could not be clearly visualized, neither inside nor outside endocytic 
vesicles. This was due, on one hand, to the low resolution in the x-y plane, 
and on the other hand, due to the backscattered electron signal. Moreover, 
it must be pointed that the presence of bare resin in the lumen of the 
capillary caused electrical charging of the sample, and consequently, tissue 
deterioration or breakage. 
 Due to these technical problems, a second attempt with higher 
magnification imaging (>30,000×) of the capillary segments was 
considered, avoiding the inclusion of the whole lumen in the region of 
interest (ROI). We used an incident electron beam with an energy of                
3.5 kV and spot size 3, and a chamber pressure of 50 Pa was applied to 
scan across the samples at a pixel dwell time of 60 µs. At this level of 
magnification, BCEC segments and the basal lamina of the endothelium 
could be observed, as well as both the vesicles inside the BCECs and the 
AuNPs contained in them. The sequential images in the stack allowed us to 
3D render structures such as the basal lamina or the vesicles located inside 
the BCECs by manually tracing the area in consecutive planes (Figure 10). 
Although the AuNPs were visible, due to their small size, it was 
impossible to 3D render them using this method; they are located in one or 
another section, but never in more than one, so it was impossible to 
reconstruct these particles in 3D by manually tracing the area across 
consecutive planes. Thus, a copy of the stack was preprocessed using the 
Fiji software to later replace the AuNPs in each section by 3D spheres of 
similar size (20 nm diameter) in Imaris. Since the AuNPs are the darkest 
structures in these images, they could be segmented with the Fiji software 
using a low threshold value. After segmentation, the resulting binary 
particles were split using a watershed to allow individual reconstruction. 
The final binary stack of images was loaded into Imaris as an additional 
channel of the original stack and the AuNPs were rendered as spheres in 
the final 3D reconstruction.  
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Figure 9. (A1-C1) Three selected serial images from an SBF-SEM                         
low-magnification image stack. (A2-C2) Colored areas represent some of the 
structures that were selected and manually traced in A1-C1, respectively, for the 
subsequent 3D reconstruction. (D1-D3) Three snapshots of the video showing the 
3D reconstruction: (D1) Two adjacent endothelial cells (ec1 and ec2) can be 
observed. Image B1 is superimposed on the reconstruction. (D2) A pericyte 
rendering is added to the reconstruction. (D3) The complete 3D reconstruction of 
the BBB segment, which includes the renderings of the two adjacent endothelial 
cells, the pericyte and two astrocytic endfeet (ae1 and ae2). Ec: endothelial cell;                 
p: pericyte; ae: astrocytic endfeet. Scale bar: 5 µm [adapted from 25]. 
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Figure 10. (A1-A6) Six selected serial images from an SBF-SEM high-magnification 
image stack. Arrows indicate the same vesicle sectioned on different planes. (B3-B6) 
Original insets from A3 and A6, respectively, in which the brightness and contrast 
have been modified to enhance visualization of the AuNPs. (D3 and D6) Images 
corresponding, respectively, to the insets from A3 and A6 that were obtained after 
applying the process of binarization, which permits to localize the AuNPs. (E1 and 
F1) Representative images of the 3D reconstruction of the SBF-SEM                            
high-magnification image stack that contains images A1-A6. AuNPs are represented 
as green spheres. Blue regions are the endothelial vesicles. bm: basal lamina;                
lum: lumen of the capillary. (E2 and F2) Insets from E1 and F1, respectively. Arrow 
in E2 indicates some AuNPs that have lost the connection with the vesicular 
membrane, while in F2 it shows some ones in which the connection is maintained. 
Scale bar: 2 µm [adapted from 25]. 
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 Thus, this level of magnification and this strategy allowed for reliable 
3D reconstructions in which the structures of the BBB, such as the basal 
lamina of the endothelium and the vesicles located in the BCECs, as well 
as the precise location of the AuNPs could be visualized simultaneously 
(Figure 10). 
 Regarding the shape of the vesicles, the 3D reconstruction allowed us 
to observe that although some of the AuNP-containing vesicles present a 
spherical or ellipsoidal form, they are often branched structures with 
irregular shapes, which sometimes even seem to merge with each other 
forming a complex endosomal network. As can be observed in Figure 10, 
some vesicles that show a spherical or ellipsoidal shape in a 2D plane can 
be considered part of a complex and irregular when subsequent sections 
are analyzed as a whole 3D structure. 
 We can conclude from this work that low-magnification imaging 
permits acquiring images of a large field of view and monitoring of 
relatively long capillary segments (more than 10 µm long), so that results 
appropriate for the identification and 3D reconstruction of cellular 
elements and some subcellular elements as nuclei. However, this resolution 
was too low for clear identification of the AuNPs. This led us to increase 
the level of magnification and re-establish the setting parameters for the 
SBF-SEM system. A higher accelerating voltage allowed the acquisition of 
higher magnification images, with sufficient resolution for AuNP 
visualization. We therefore achieved the goal of 3D reconstructing BBB 
segments and AuNP-containing vesicles, as well as precisely localizing the 
AuNPs within the cellular structures. We observed that the vesicles 
containing AuNPs are often branched structures with irregular shapes, 
which sometimes even seem to merge with each other forming a complex 
endosomal network. Moreover, we applied an innovative method by which 
the AuNPs were replaced by 3D spheres of similar size at the exact same 




 Altogether, the different studies exposed in the present work, allowed 
us to clarify some doubtful aspects concerning the transport of drugs 
across the BBB using RMT and anti-TfR mAbs. These aspects, which are 
summarized in Figure 11, permit to conclude that: 
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1. The 8D3 antibody is capable of recognizing and binding to the TfR 
present in the luminal membrane of brain capillary endothelial cells 
following in vivo administration. 
2. The 8D3 antibody is internalized inside the brain capillary endothelial 
cells after its binding to the TfR. 
3. The 8D3 antibody is able to trigger the internalization of the cargo 
which is conjugated to, overcoming the first obstacle in the transport 
across the brain capillary endothelial cells. 
4. The internalized cargo can vary in size and nature, ranging from 
proteins like the Fab’ fragments of antibodies to larger particles like 
AuNPs measuring 20 nm in diameter. 
5. The internalization of 8D3 and its cargo is produced by a                  
clathrin-dependent endocytosis process. 
6. Most of the resulting endocytic vesicles undergo a process of fusion, 
maturation and reorganization in which the 8D3-cargo complexes that 
are inside them progressively accumulate in endosomal networks of 
great complexity. 
7. During the processing of these vesicles the interaction between TfR, 
8D3 and/or cargo is lost. 
8. Nonetheless, some endocytic vesicles containing the 8D3-cargo 
complexes complete transcytosis. 
9. These vesicles fuse with the basolateral membrane and open up to the 
basal lamina. 
10. When fused with the basolateral membrane, the 8D3-cargo complexes 
become exposed to the basal lamina.  
11. Exposed 8D3-cargo complexes remain attached to the TfR and fail to 
go beyond the basal lamina.  
12. In order to facilitate the cargo liberation to the brain parenchyma, it is 
necessary to modify and optimize the linkages between the 8D3 and 
the cargo and/or the linkage between the 8D3 and the TfR. 
13. Although some improvements at the design level of the constructs are 
needed, the use of the RMT system and mAbs directed against 
transcytosis receptors is a strategy with great potential for transporting 
drugs through the BBB. 
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Figure 11. State of the art of both the transport of drugs across the BBB using                 




 This work is a summary of the doctorate thesis of Itsaso Cabezón, 
carried out in the Blood Brain Barrier Research Group from the Universitat 
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